Circulation. 2004;109:2050-2053
Published online before print April 26, 2004, doi: 10.1161/01.CIR.0000127954.98131.23
Published online before print April 26, 2004, doi: 10.1161/01.CIR.0000127954.98131.23
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;109:2050-2053.)
© 2004 American Heart Association, Inc.
Brief Rapid Communications |
Phosphatidylinositol-3-Kinase Signaling Is Required for Erythropoietin-Mediated Acute Protection Against Myocardial Ischemia/Reperfusion Injury
From the Institute for Cell Engineering, McKusick-Nathans Institute of Genetic Medicine, and Department of Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, Md.
Correspondence to Dr Gregg L. Semenza, 733 N Broadway, Suite 671, Baltimore, MD 21205. E-mail gsemenza{at}jhmi.edu
Received November 7, 2003; de novo received January 22, 2004; revision received March 23, 2004; accepted March 23, 2004.
Background— Parenteral administration of recombinant human erythropoietin (rhEPO) to rats induces protection against myocardial ischemia/reperfusion injury 24 hours later. However, the mechanisms by which rhEPO mediates protection have not been determined.
Methods and Results— rhEPO was perfused into isolated rat hearts over 15 minutes immediately before 30 minutes of no-flow ischemia and 45 minutes of reperfusion. Compared with saline-perfused control hearts, recovery of left ventricular developed pressure was increased in rhEPO-perfused hearts. rhEPO also increased AKT activity and decreased apoptosis. All of these effects were blocked when the phosphatidylinositol-3-kinase inhibitor wortmannin was infused with rhEPO.
Conclusions— rhEPO provides immediate protection against ischemia/reperfusion injury in the isolated perfused rat heart that is mediated by the phosphatidylinositol-3-kinase pathway.
Key Words: erythropoietin • ischemia • reperfusion • myocardial infarction
This article has been cited by other articles:
 |
|
 |
|
  T. Miki, T. Miura, H. Hotta, M. Tanno, T. Yano, T. Sato, Y. Terashima, A. Takada, S. Ishikawa, and K. Shimamoto Endoplasmic Reticulum Stress in Diabetic Hearts Abolishes Erythropoietin-Induced Myocardial Protection by Impairment of Phospho-Glycogen Synthase Kinase-3{beta}-Mediated Suppression of Mitochondrial Permeability Transition Diabetes, December 1, 2009; 58(12): 2863 - 2872. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Smith, D. Semple, S. Bhandari, and A.-M. L. Seymour Cellular basis of uraemic cardiomyopathy: a role for erythropoietin? Eur J Heart Fail, August 1, 2009; 11(8): 732 - 738. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Strande, M. E. Widlansky, N. E. Tsopanoglou, J. Su, J. Wang, A. Hsu, K. V. Routhu, and J. E. Baker Parstatin: a cryptic peptide involved in cardioprotection after ischaemia and reperfusion injury Cardiovasc Res, July 15, 2009; 83(2): 325 - 334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Bonder, W. Y. Sun, T. Matthews, C. Cassano, X. Li, H. S. Ramshaw, S. M. Pitson, A. F. Lopez, P. T. Coates, R. L. Proia, et al. Sphingosine kinase regulates the rate of endothelial progenitor cell differentiation Blood, February 26, 2009; 113(9): 2108 - 2117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Brunner, J. Winogradow, B. C. Huber, M.-M. Zaruba, R. Fischer, R. David, G. Assmann, N. Herbach, R. Wanke, J. Mueller-Hoecker, et al. Erythropoietin administration after myocardial infarction in mice attenuates ischemic cardiomyopathy associated with enhanced homing of bone marrow-derived progenitor cells via the CXCR-4/SDF-1 axis FASEB J, February 1, 2009; 23(2): 351 - 361. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Burger, F. Xiang, L. Hammoud, X. Lu, and Q. Feng Role of heme oxygenase-1 in the cardioprotective effects of erythropoietin during myocardial ischemia and reperfusion Am J Physiol Heart Circ Physiol, January 1, 2009; 296(1): H84 - H93. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Breggia, D. M. Wojchowski, and J. Himmelfarb JAK2/Y343/STAT5 signaling axis is required for erythropoietin-mediated protection against ischemic injury in primary renal tubular epithelial cells Am J Physiol Renal Physiol, December 1, 2008; 295(6): F1689 - F1695. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Rastogi, M. Imai, V. G. Sharov, S. Mishra, and H. N. Sabbah Darbepoetin-{alpha} prevents progressive left ventricular dysfunction and remodeling in nonanemic dogs with heart failure Am J Physiol Heart Circ Physiol, December 1, 2008; 295(6): H2475 - H2482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Doue, K. Ohtsuki, K. Ogawa, M. Ueda, A. Azuma, H. Saji, H. W. Strauss, and H. Matsubara Cardioprotective Effects of Erythropoietin in Rats Subjected to Ischemia-Reperfusion Injury: Assessment of Infarct Size with 99mTc-Annexin V J. Nucl. Med., October 1, 2008; 49(10): 1694 - 1700. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Nishida, T. Sato, M. Miyazaki, and H. Nakaya Infarct size limitation by adrenomedullin: protein kinase A but not PI3-kinase is linked to mitochondrial KCa channels Cardiovasc Res, January 15, 2008; 77(2): 398 - 405. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. van Albada, G. J. du Marchie Sarvaas, J. Koster, M. C. Houwertjes, R. M. F. Berger, and R. G. Schoemaker Effects of erythropoietin on advanced pulmonary vascular remodelling Eur. Respir. J., January 1, 2008; 31(1): 126 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.-H. Kim, G. Y. Oudit, and P. H. Backx Erythropoietin Protects against Doxorubicin-Induced Cardiomyopathy via a Phosphatidylinositol 3-Kinase-Dependent Pathway J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 160 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ferrario, M. Massa, V. Rosti, R. Campanelli, M. Ferlini, B. Marinoni, G. M. De Ferrari, V. Meli, M. De Amici, A. Repetto, et al. Early haemoglobin-independent increase of plasma erythropoietin levels in patients with acute myocardial infarction Eur. Heart J., August 1, 2007; 28(15): 1805 - 1813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Gao, M. Boucher, J. K. Chuprun, R.-H. Zhou, A. D. Eckhart, and W. J. Koch Darbepoetin alfa, a long-acting erythropoietin analog, offers novel and delayed cardioprotection for the ischemic heart Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H60 - H68. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Lipsic, R. G. Schoemaker, P. van der Meer, A. A. Voors, D. J. van Veldhuisen, and W. H. van Gilst Protective Effects of Erythropoietin in Cardiac Ischemia: From Bench to Bedside J. Am. Coll. Cardiol., December 5, 2006; 48(11): 2161 - 2167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nishihara, T. Miura, T. Miki, J. Sakamoto, M. Tanno, H. Kobayashi, Y. Ikeda, K. Ohori, A. Takahashi, and K. Shimamoto Erythropoietin affords additional cardioprotection to preconditioned hearts by enhanced phosphorylation of glycogen synthase kinase-3beta Am J Physiol Heart Circ Physiol, August 1, 2006; 291(2): H748 - H755. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Tada, Y. Kagaya, M. Takeda, J. Ohta, Y. Asaumi, K. Satoh, K. Ito, A. Karibe, K. Shirato, N. Minegishi, et al. Endogenous erythropoietin system in non-hematopoietic lineage cells plays a protective role in myocardial ischemia/reperfusion Cardiovasc Res, August 1, 2006; 71(3): 466 - 477. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Khan, S. Varadharaj, L. P. Ganesan, J. C. Shobha, M. U. Naidu, N. L. Parinandi, S. Tridandapani, V. K. Kutala, and P. Kuppusamy C-phycocyanin protects against ischemia-reperfusion injury of heart through involvement of p38 MAPK and ERK signaling Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H2136 - H2145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Miki, T. Miura, T. Yano, A. Takahashi, J. Sakamoto, M. Tanno, H. Kobayashi, Y. Ikeda, M. Nishihara, K. Naitoh, et al. Alteration in Erythropoietin-Induced Cardioprotective Signaling by Postinfarct Ventricular Remodeling J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 68 - 75. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kempf, M. Eden, J. Strelau, M. Naguib, C. Willenbockel, J. Tongers, J. Heineke, D. Kotlarz, J. Xu, J. D. Molkentin, et al. The Transforming Growth Factor-{beta} Superfamily Member Growth-Differentiation Factor-15 Protects the Heart From Ischemia/Reperfusion Injury Circ. Res., February 17, 2006; 98(3): 351 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bae and L. Zhang Gender Differences in Cardioprotection against Ischemia/Reperfusion Injury in Adult Rat Hearts: Focus on Akt and Protein Kinase C Signaling J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1125 - 1135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Maloyan, L. Eli-Berchoer, G. L. Semenza, G. Gerstenblith, M. D. Stern, and M. Horowitz HIF-1{alpha}-targeted pathways are activated by heat acclimation and contribute to acclimation-ischemic cross-tolerance in the heart Physiol Genomics, September 21, 2005; 23(1): 79 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. van der Meer, E. Lipsic, R. H. Henning, K. Boddeus, J. van der Velden, A. A. Voors, D. J. van Veldhuisen, W. H. van Gilst, and R. G. Schoemaker Erythropoietin Induces Neovascularization and Improves Cardiac Function in Rats With Heart Failure After Myocardial Infarction J. Am. Coll. Cardiol., July 5, 2005; 46(1): 125 - 133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Rui, Q. Feng, M. Lei, T. Peng, J. Zhang, M. Xu, E. Dale Abel, A. Xenocostas, and P. R. Kvietys Erythropoietin prevents the acute myocardial inflammatory response induced by ischemia/reperfusion via induction of AP-1 Cardiovasc Res, February 15, 2005; 65(3): 719 - 727. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Maiese, F. Li, and Z. Z. Chong New Avenues of Exploration for Erythropoietin JAMA, January 5, 2005; 293(1): 90 - 95. [Abstract] [Full Text] [PDF]
|
|